GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (STU:CU2) » Definitions » Cyclically Adjusted Price-to-FCF

Cerus (STU:CU2) Cyclically Adjusted Price-to-FCF : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is Cerus Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cerus Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Cerus's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Cyclically Adjusted Price-to-FCF Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cerus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cerus's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Cerus's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cerus's Cyclically Adjusted Price-to-FCF falls into.



Cerus Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Cerus's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Cerus's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.004/131.7762*131.7762
=0.004

Current CPI (Mar. 2024) = 131.7762.

Cerus Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.101 100.560 -0.132
201409 -0.126 100.428 -0.165
201412 -0.088 99.070 -0.117
201503 -0.154 99.621 -0.204
201506 -0.140 100.684 -0.183
201509 -0.110 100.392 -0.144
201512 -0.083 99.792 -0.110
201603 -0.118 100.470 -0.155
201606 -0.128 101.688 -0.166
201609 -0.143 101.861 -0.185
201612 -0.091 101.863 -0.118
201703 -0.149 102.862 -0.191
201706 -0.112 103.349 -0.143
201709 -0.098 104.136 -0.124
201712 -0.074 104.011 -0.094
201803 -0.067 105.290 -0.084
201806 -0.059 106.317 -0.073
201809 -0.034 106.507 -0.042
201812 -0.049 105.998 -0.061
201903 -0.165 107.251 -0.203
201906 -0.103 108.070 -0.126
201909 -0.156 108.329 -0.190
201912 -0.055 108.420 -0.067
202003 -0.116 108.902 -0.140
202006 -0.045 108.767 -0.055
202009 -0.028 109.815 -0.034
202012 -0.046 109.897 -0.055
202103 -0.088 111.754 -0.104
202106 -0.042 114.631 -0.048
202109 -0.034 115.734 -0.039
202112 -0.009 117.630 -0.010
202203 -0.112 121.301 -0.122
202206 -0.002 125.017 -0.002
202209 -0.015 125.227 -0.016
202212 -0.016 125.222 -0.017
202303 -0.053 127.348 -0.055
202306 -0.048 128.729 -0.049
202309 -0.068 129.860 -0.069
202312 -0.077 129.419 -0.078
202403 0.004 131.776 0.004

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cerus  (STU:CU2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Cerus Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Cerus's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (STU:CU2) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Cerus (STU:CU2) Headlines

No Headlines